Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap Down – Here’s Why

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) gapped down before the market opened on Monday . The stock had previously closed at $25.36, but opened at $24.07. Damora Therapeutics, Inc. Common Stock shares last traded at $26.86, with a volume of 15,596 shares traded.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Royal Bank Of Canada assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They set an “outperform” rating and a $40.00 price target for the company. Guggenheim reiterated a “buy” rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Lifesci Capital upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd. Leerink Partners started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $46.00 target price for the company. Finally, Evercore started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Damora Therapeutics, Inc. Common Stock currently has an average rating of “Moderate Buy” and an average price target of $43.40.

Damora Therapeutics, Inc. Common Stock Price Performance

The business has a 50 day moving average of $26.63 and a 200 day moving average of $23.21. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -2.18 and a beta of 1.50.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of large investors have recently bought and sold shares of DMRA. Two Sigma Investments LP bought a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter valued at $76,000. Virtu Financial LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter valued at $49,000. Connective Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at about $100,000. Sigma Planning Corp bought a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $334,000. Finally, Geode Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $266,000. 14.20% of the stock is currently owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.